An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who
meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic
transdermal patch) for acute migraine attacks over a 12 month period.